000305452 001__ 305452
000305452 005__ 20251026023407.0
000305452 0247_ $$2doi$$a10.1002/cncr.70131
000305452 0247_ $$2pmid$$apmid:41108673
000305452 0247_ $$2ISSN$$a1934-662X
000305452 0247_ $$2ISSN$$a0008-543X
000305452 0247_ $$2ISSN$$a1045-7410
000305452 0247_ $$2ISSN$$a1097-0142
000305452 0247_ $$2ISSN$$a1934-6638
000305452 0247_ $$2altmetric$$aaltmetric:182706034
000305452 037__ $$aDKFZ-2025-02170
000305452 041__ $$aEnglish
000305452 082__ $$a610
000305452 1001_ $$00009-0000-8474-4039$$aGogebakan, Kemal Caglar$$b0
000305452 245__ $$aProstate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival.
000305452 260__ $$aNew York, NY$$bWiley-Liss$$c2025
000305452 3367_ $$2DRIVER$$aarticle
000305452 3367_ $$2DataCite$$aOutput Types/Journal article
000305452 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761038231_1536449
000305452 3367_ $$2BibTeX$$aARTICLE
000305452 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305452 3367_ $$00$$2EndNote$$aJournal Article
000305452 500__ $$aISSN 1097-0142
000305452 520__ $$aProstate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) is affecting the management of patients with prostate cancer with biochemical recurrence after radical prostatectomy. The long-term outcomes of tailoring salvage treatment on the basis of PSMA-PET/CT status remain to be determined.A decision-analytic model was developed to project incremental life-years of strategies that allocate treatments at biochemical recurrence after radical prostatectomy on the basis of PSMA-PET/CT status (PSMA-metastatic vs. PSMA-nonmetastatic). Modeled treatments are local/regional (radiation) or systemic (hormone therapy and doublet therapy), administered immediately or delayed. PSMA-metastatic status was assumed to lead to treatment intensification, whereas PSMA-nonmetastatic status would lead to deintensification. To project survival, data on progression to metastasis from a clinical cohort were combined with registry data on postmetastasis survival. Because of the lack of data on long-term treatment benefits by PSMA status, survival was projected by varying the hazard ratio (HR) for disease-specific death among PSMA-metastatic versus PSMA-nonmetastatic patients under delayed or local/regional regimens (HR1) and under immediate systemic regimens (HR2).Mean life-years are projected to be 15.5 under the non-PSMA-tailored strategy, and mean incremental life-years range from 0.38 to 0.81 depending on HR1 and HR2. A greater benefit is projected when PSMA-metastatic status is more adverse under salvage regimens that do not include systemic agents.This decision-analytic modeling study projects that PSMA-PET/CT-guided management at biochemical recurrence after radical prostatectomy yields a modest survival benefit under the specified model inputs and assumptions regarding treatment distributions. These findings may complement emerging data on the corresponding economic costs and health-related quality of life.
000305452 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000305452 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305452 650_7 $$2Other$$abiochemical recurrence
000305452 650_7 $$2Other$$adecision‐analytic model
000305452 650_7 $$2Other$$aprostate cancer
000305452 650_7 $$2Other$$aprostate‐specific membrane antigen positron emission tomography/computed tomography (PSMA‐PET/CT)
000305452 650_7 $$0EC 3.4.17.21$$2NLM Chemicals$$aGlutamate Carboxypeptidase II
000305452 650_7 $$0EC 3.4.17.21$$2NLM Chemicals$$aFOLH1 protein, human
000305452 650_7 $$2NLM Chemicals$$aAntigens, Surface
000305452 650_2 $$2MeSH$$aHumans
000305452 650_2 $$2MeSH$$aMale
000305452 650_2 $$2MeSH$$aProstatic Neoplasms: diagnostic imaging
000305452 650_2 $$2MeSH$$aProstatic Neoplasms: mortality
000305452 650_2 $$2MeSH$$aProstatic Neoplasms: surgery
000305452 650_2 $$2MeSH$$aProstatic Neoplasms: pathology
000305452 650_2 $$2MeSH$$aProstatic Neoplasms: therapy
000305452 650_2 $$2MeSH$$aProstatectomy
000305452 650_2 $$2MeSH$$aPositron Emission Tomography Computed Tomography: methods
000305452 650_2 $$2MeSH$$aNeoplasm Recurrence, Local: diagnostic imaging
000305452 650_2 $$2MeSH$$aNeoplasm Recurrence, Local: mortality
000305452 650_2 $$2MeSH$$aGlutamate Carboxypeptidase II: metabolism
000305452 650_2 $$2MeSH$$aAntigens, Surface: metabolism
000305452 650_2 $$2MeSH$$aSalvage Therapy
000305452 650_2 $$2MeSH$$aAged
000305452 650_2 $$2MeSH$$aMiddle Aged
000305452 7001_ $$00000-0001-6931-4962$$aElsisi, Zizi$$b1
000305452 7001_ $$aMontano-Campos, Felipe$$b2
000305452 7001_ $$00000-0002-5149-5379$$aOwens, Lukas$$b3
000305452 7001_ $$aZhao, Yibai$$b4
000305452 7001_ $$00000-0002-7592-6567$$aGulati, Roman$$b5
000305452 7001_ $$aFerdinandus, Justin$$b6
000305452 7001_ $$0P:(DE-HGF)0$$aFendler, Wolfgang P$$b7
000305452 7001_ $$aCalais, Jeremie$$b8
000305452 7001_ $$aHope, Thomas A$$b9
000305452 7001_ $$aCarlsson, Sigrid$$b10
000305452 7001_ $$aFainberg, Jonathan$$b11
000305452 7001_ $$aLaudone, Vincent$$b12
000305452 7001_ $$aKunst, Natalia$$b13
000305452 7001_ $$aBerlin, Alejandro$$b14
000305452 7001_ $$aSchipper, Matthew$$b15
000305452 7001_ $$aBarbour, Andrew$$b16
000305452 7001_ $$aIravani, Amir$$b17
000305452 7001_ $$aEtzioni, Ruth$$b18
000305452 773__ $$0PERI:(DE-600)1479932-7$$a10.1002/cncr.70131$$gVol. 131, no. 21, p. e70131$$n21$$pe70131$$tCancer$$v131$$x0008-543X$$y2025
000305452 909CO $$ooai:inrepo02.dkfz.de:305452$$pVDB
000305452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000305452 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000305452 9141_ $$y2025
000305452 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-21$$wger
000305452 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-21
000305452 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-21
000305452 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000305452 980__ $$ajournal
000305452 980__ $$aVDB
000305452 980__ $$aI:(DE-He78)ED01-20160331
000305452 980__ $$aUNRESTRICTED